Candel Therapeutics Inc.

NASDAQ: CADL · Real-Time Price · USD
6.05
0.01 (0.17%)
At close: Aug 15, 2025, 3:59 PM
6.05
-0.06%
After-hours: Aug 15, 2025, 06:20 PM EDT

Candel Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
n/a n/a 1.78M 1.78M 1.78M 1.78M 31K 62K 93K 124K 124K 124K 124K 124K 124K 124K 124K
Cost of Revenue
249K 500K 812K 1.12M 1.16M 913K 877K 829K 772K 987K 889K 5.9M 8.95M 11.49M 11.31M 6.04M 4.55M
Gross Profit
-249K -500K 964K 658K 612K 863K -846K -767K -679K -863K -765K -5.77M -8.83M -11.36M -11.19M -5.92M -4.42M
Operating Income
-33.6M -33.37M -35.55M -35.65M -36.66M -38.39M -36.17M -36.19M -35.37M -34.72M -34.36M -33.51M -30.06M -25.73M -24.11M -18.83M -16.15M
Interest Income
1.7M 1.09M 1.21M 1.48M 1.69M 2.08M 1.67M 1.51M 1.12M 413K 413K 70K n/a n/a 49K 90K 184K
Pretax Income
-39.58M -55.18M -52.2M -49.99M -37.37M -37.94M -31.93M -32.18M -26.71M -18.79M -12.12M -19.59M -32.52M -36.12M -48.2M -34.59M -20.39M
Net Income
-39.58M -55.18M -52.2M -49.99M -37.37M -37.94M -16.19M -16.25M -6.18M 9.85M 794K -6.87M -24.41M -36.12M -48.2M -34.59M -20.39M
Selling & General & Admin
14.37M 14.06M 13.79M 13.47M 13.52M 13.88M 13.98M 14.51M 14.62M 14.06M 14.81M 14.07M 12.35M 10.69M 9.39M 7.56M 6.38M
Research & Development
19.23M 19.06M 21.19M 21.62M 22.58M 24.19M 22.22M 21.75M 20.84M 20.79M 19.67M 19.56M 17.83M 15.16M 14.84M 11.39M 9.89M
Other Expenses
n/a n/a 12K 12K 12K 12K -48K 5.3M 10.29M 15.67M 31.7M 18.11M 747K -4.83M -25.36M -17.27M -5.41M
Operating Expenses
33.6M 33.12M 34.98M 35.09M 36.09M 38.07M 36.15M 36.2M 35.41M 34.8M 34.34M 33.35M 29.3M 24.77M 23.16M 17.86M 15.62M
Interest Expense
1.75M 2.09M 2.37M 2.56M 2.63M 2.6M 2.59M 2.44M 2.23M 1.79M 1.14M 635K 215K 52K 90K 76K 155K
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
26.22M 34.12M 35.55M 35.65M 36.65M 38.38M 36.15M 36.2M 35.41M 34.8M 34.34M 33.35M 29.3M 24.77M 23.16M 17.86M 15.62M
Income Tax Expense
n/a n/a n/a n/a n/a n/a -15.73M -15.93M -20.53M -28.64M -12.9M -12.69M -8.07M 41K 29K 15K n/a
Shares Outstanding (Basic)
31.68M 35.56M 32.01M 29.88M 29.2M 28.98M 28.92M 28.92M 28.92M 28.9M 28.89M 28.81M 28.69M 23.33M 23.33M 24.8M 18.71M
Shares Outstanding (Diluted)
31.68M 35.56M 32.01M 29.88M 29.2M 28.98M 28.92M 28.92M 28.92M 28.9M 28.89M 28.81M 28.69M 23.33M 23.33M 24.8M 18.71M
EPS (Basic)
-1.28 -1.79 -1.73 -1.69 -1.28 -1.3 -0.55 -0.55 -0.2 0.35 0.04 -0.36 -1.06 -1.55 -2.18 -1.63 -1.09
EPS (Diluted)
-1.28 -1.79 -1.73 -1.69 -1.28 -1.3 -0.55 -0.55 -0.2 0.35 0.04 -0.36 -1.06 -1.55 -2.18 -1.63 -1.09
EBITDA
-52.9M -52.1M -48.77M -46.31M -33.57M -34.2M -31.97M -32.77M -27.64M -28.5M -18.84M -18.61M -20.37M -15.98M -23.74M -18.22M -15.37M
EBIT
-45.51M -53.09M -49.83M -47.43M -34.73M -35.34M -33.02M -33.77M -28.58M -29.38M -19.68M -19.19M -20.71M -16.19M -23.77M -18.34M -15.5M
Depreciation & Amortization
739K 990K 1.06M 1.12M 1.16M 1.14M 1.11M 1.06M 1M 987K 889K 653K 436K 247K 75K 98K 85K